Abstract P141: Preclinical characterization of LOX-24350, a highly potent and isoform-selective FGFR3 inhibitor
Joshua A. Ballard(Loxo Oncology at Lilly (United States)), Steven W. Andrews(Loxo Oncology at Lilly (United States)), Thomas C. Buckles(Loxo Oncology at Lilly (United States)), Severine Gharbi(Ludwig Cancer Research), Timothy Kercher(Loxo Oncology at Lilly (United States)), David Abraham(University College London), Barbara J. Brandhuber(Loxo Oncology at Lilly (United States)), Faith D. Watson(Loxo Oncology at Lilly (United States)), Nisha R. Patel(Loxo Oncology at Lilly (United States)), Nathan A. Brooks(Eli Lilly (United States)), Kaveri Urkalan(Loxo Oncology at Lilly (United States)), Kevin Ebata(Memorial Sloan Kettering Cancer Center), Shane Walls(Loxo Oncology at Lilly (United States)), David A. Busha(Loxo Oncology at Lilly (United States)), Desta Bume(Loxo Oncology at Lilly (United States)), Tony Morales(Loxo Oncology at Lilly (United States)), Ryan Brecht(Loxo Oncology at Lilly (United States)), Ernst Peder Cedervall(Loxo Oncology at Lilly (United States)), Kevin R. Condroski(Loxo Oncology at Lilly (United States)), Peiyi Yang(Loxo Oncology at Lilly (United States)), Sandra Gomez Villalain(Eli Lilly (Spain)), Jessica D. Podoll(Loxo Oncology at Lilly (United States)), Robert A. Hazlitt(Loxo Oncology at Lilly (United States))
Cited by 11
Related Papers
Systemic sclerosis: a prototypic multisystem fibrotic disorder
|Journal of Clinical Investigation|2007|1.1k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
|New England Journal of Medicine|2020|766
Exploring the specificity of the PI3K family inhibitor LY294002
|Biochemical Journal|2007|463